ライフサイエンスコーパス: nosocomial infection

1 hazard for women of childbearing age or as a nosocomial infection.

2 novel avenues for therapy and prevention of nosocomial infection.

3 C5a-mediated dysfunction and acquisition of nosocomial infection.

4 ogen Clostridium difficile, a major cause of nosocomial infection.

5 r developing fecal carriage that may lead to nosocomial infection.

6 ated pneumonia (VAP) is a common and serious nosocomial infection.

7 t hosts, but they are also leading causes of nosocomial infection.

8 ave shown mixed results in the prevention of nosocomial infection.

9 ated with levels of the type 2 cytokines and nosocomial infection.

10 mechanisms used by E. faecalis to establish nosocomial infection.

11 nit length of stay >48 hrs were followed for nosocomial infection.

12 of packed red blood cells is associated with nosocomial infection.

13 n, immunosuppression, and the development of nosocomial infection.

14 , especially among microorganisms that cause nosocomial infection.

15 coccus faecium (VREfm) is a leading cause of nosocomial infection.

16 e L. pneumophila population as the source of nosocomial infection.

17 hylococcus aureus (MRSA) is a major cause of nosocomial infection.

18 tobacter baumannii is a significant cause of nosocomial infection.

19 s associated with an increased risk for VLBW nosocomial infection.

20 an opportunistic pathogen that causes severe nosocomial infections.

21 medical environment and causes severe human nosocomial infections.

22 of the predominant bacterium encountered in nosocomial infections.

23 nantly in (sub)species that frequently cause nosocomial infections.

24 c concern for food safety, bioterrorism, and nosocomial infections.

25 become one of the most prevalent and costly nosocomial infections.

26 associated with increased risk of death and nosocomial infections.

27 ticularly high-risk population to intestinal nosocomial infections.

28 ally ill patients are at heightened risk for nosocomial infections.

29 ment of tuberculosis, HIV, and perinatal and nosocomial infections.

30 nts may respond to lung injury and postnatal nosocomial infections.

31 eus is an important cause of mortality among nosocomial infections.

32 as recently emerged as an important cause of nosocomial infections.

33 d to the emergence of E. faecium and CC17 in nosocomial infections.

34 toward reductions in ICU length of stay and nosocomial infections.

35 both responses to lung injury and postnatal nosocomial infections.

36 soil and water and are an important cause of nosocomial infections.

37 MRSA) has created challenges in treatment of nosocomial infections.

38 ic pathogens and among the leading causes of nosocomial infections.

39 s responsible for approximately one-third of nosocomial infections.

40 e of the most commonly isolated organisms in nosocomial infections.

41 nd from patients with food-borne disease and nosocomial infections.

42 nd associated means to control P. aeruginosa nosocomial infections.

43 c fibrosis patients and is a major source of nosocomial infections.

44 ere associated with subsequent occurrence of nosocomial infections.

45 a, especially during food-borne outbreaks or nosocomial infections.

46 DUWL biofilm may have beneficial effects on nosocomial infections.

47 dysfunction responsible for poor outcome and nosocomial infections.

48 ding causes of bacteraemia and other serious nosocomial infections.

49 aureus is a common pathogen associated with nosocomial infections.

50 most frequently associated with outbreaks of nosocomial infections.

51 cost-effective mechanism to monitor emerging nosocomial infections.

52 as been associated with an increased risk of nosocomial infections.

53 ections at surgical sites and prevents other nosocomial infections.

54 testinal tract (GIT) and an agent of serious nosocomial infections.

55 nce of inadequate antimicrobial treatment of nosocomial infections.

56 rence of inadequate antibiotic treatment for nosocomial infections.

57 ndependently associated with higher risk for nosocomial infections.

58 vasive devices made up the great majority of nosocomial infections.

59 s of bacteria, particularly in those causing nosocomial infections.

60 a L. pneumophila population responsible for nosocomial infections.

61 ingly been recognized as a major pathogen in nosocomial infections.

62 evices, it has emerged as a leading cause of nosocomial infections.

63 h, sexually transmitted infections and major nosocomial infections.

64 ve bacterium responsible for a wide range of nosocomial infections.

65 responsible for up to 10% of gram-negative, nosocomial infections.

66 56 inpatients, 63% were classified as having nosocomial infections.

67 A) which is one of the most common causes of nosocomial infections.

68 ity of pathogens to evolve in the context of nosocomial infections.

69 shock and correlated to adverse outcomes or nosocomial infections.

70 ic fibrosis patients and is a major agent of nosocomial infections.

71 ents were used to estimate the proportion of nosocomial infections.

72 V infections were more heterogeneous than in nosocomial infections.

73 sociated with an increased susceptibility to nosocomial infections.

74 e a modifiable risk factor for postoperative nosocomial infections.

75 y related species are commonly implicated in nosocomial infections.

76 ticular, is now one of the leading causes of nosocomial infections.

77 which is responsible for the development of nosocomial infections.

78 ida species are one of the leading causes of nosocomial infections.

79 n immune function can predispose patients to nosocomial infections.

80 humans, and is one of the leading causes of nosocomial infections.

81 ulitis are projected to cause more than 9000 nosocomial infections, 1000 to 5000 Clostridium difficil

82 ated ventilator-associated complication were nosocomial infections (27.3% and 43.8%), including venti

83 ted infection (29% versus 16%; P = 0.019) or nosocomial infection (37% versus 16%; P < 0.001) than in

84 empirical antibiotic therapy was very low in nosocomial infections (40%), compared to HCA and CA epis

85 = .49), mortality (16.3% and 9.8%, p = .38), nosocomial infections (43% vs. 57%, p = .16), and acute

86 h health care-associated infection (52%) and nosocomial infection (61%) but was uncommon in the group

87 55 years, 52% hepatitis C virus [HCV], 15.8% nosocomial infection, 96% Child score >/= 7) and 30-day

88 esponsible for large numbers of postsurgical nosocomial infections across the United States and world

89 rriers of resistant organisms, prevention of nosocomial infections, adequate hand hygiene, isolation

90 er on mortality, multiple organ failure, and nosocomial infection, after controlling for all importan

91 ng human pathogen and a significant cause of nosocomial infections among hospital patients worldwide.

92 We then compared incidence of nosocomial infections among infants in these two groups

93 These are associated with higher rates of nosocomial infections among infants with very low birth

94 organ failure is associated with subsequent nosocomial infection and increased mortality.

95 g phases II and III, the association between nosocomial infection and individual phase was not signif

96 ificantly greater in patients that developed nosocomial infection and organ dysfunction than similarl

97 about the pathophysiology of post-traumatic nosocomial infection and organ failure, findings have be

98 njury is common, but is often complicated by nosocomial infection and organ failure.

99 The associations between nosocomial infection and patient age, sex, and NoV genot

100 eumoniae, which are frequently implicated in nosocomial infection and preterm infant gut colonization

101 i (MRS) are one of the most common causes of nosocomial infections and bacteremia.

102 unsaturated fatty acids on the prevalence of nosocomial infections and clinical outcomes in medical a

103 Enterococci account for nearly 10% of all nosocomial infections and constitute a significant treat

104 common opportunistic pathogen implicated in nosocomial infections and in chronic lung infections in

105 yunsaturated fatty acids reduces the risk of nosocomial infections and increases the predicted time f

106 ient transfers, contributes to the spread of nosocomial infections and investigate how network struct

107 Enterococcus faecalis is a leading cause of nosocomial infections and is known for its ability to ac

108 an important opportunistic pathogen causing nosocomial infections and is often associated with infec

109 and M. abscessus, have been associated with nosocomial infections and occupational hypersensitivity

110 Furthermore, complications like nosocomial infections and organ failure are not associat

111 Acinetobacter baumannii frequently causes nosocomial infections and outbreaks.

112 1 are associated with a higher incidence of nosocomial infections and seem to be major actors of sep

113 intervention to help reduce the incidence of nosocomial infections and sepsis postburn.

114 blood transfusions had a higher incidence of nosocomial infections and sepsis, and the amount of bloo

115 These organisms are a major concern in nosocomial infections and should therefore be monitored

116 nfections (UTIs) are the most common type of nosocomial infection, and Candida albicans is the most f

117 shock, while the onset of the effect of age, nosocomial infection, and cirrhosis was later.

118 cted by a nationally based system monitoring nosocomial infection, and described in a prospectively a

119 result in higher rates of organ dysfunction, nosocomial infection, and length of hospital stay.

120 to their antibiotic resistance, incidence of nosocomial infection, and person-to-person transmission.

121 HRS were age, high baseline serum bilirubin, nosocomial infection, and reduction in serum creatinine

122 lower risk-adjusted rate of 7-day mortality, nosocomial infection, and severe intraventricular hemorr

123 blood cells was related to the occurrence of nosocomial infection, and there was a dose-response patt

124 frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature,

125 ndwashing was associated with a reduction in nosocomial infections, and gown and glove isolation appe

126 ient and family verbal abuse, patient falls, nosocomial infections, and medications errors.

127 ciation between red blood cell transfusions, nosocomial infections, and poorer outcomes in critically

128 Pseudomonas aeruginosa is a leading cause of nosocomial infections, and resistance to virtually all a

129 common source of health care-associated and nosocomial infections, and Staphylococcus aureus was the

130 the immaturity of their immune systems, and nosocomial infections are a significant risk factor for

131 Nosocomial infections are responsible for significant mo

132 Nosocomial infections are those that become evident 48 h

133 Many nosocomial infections arise from gastrointestinal coloni

134 ted readmissions consistently had index-stay nosocomial infections as a predictor for HE, renal/metab

135 aureus nasal carriage and increased risk of nosocomial infection, as well as increased carriage due

136 rected for survival probability, the risk of nosocomial infection associated with red blood cell tran

137 n-resistant enterococci are a major cause of nosocomial infections but are rarely found in humans in

138 lator-associated pneumonia (VAP) is a common nosocomial infection causing significant morbidity and m

139 iated with cirrhosis severity, diabetes, and nosocomial infections; close monitoring of patients with

140 n group was six times more likely to develop nosocomial infection compared with the nontransfusion gr

141 Nosocomial infections continue to be important causes of

142 The implementation the International Nosocomial Infection Control Consortium multidimensional

143 The International Nosocomial Infection Control Consortium ventilator-assoc

144 s to analyze the effect of the International Nosocomial Infection Control Consortium's multidimension

145 etwork, and the methodology of International Nosocomial Infection Control Consortium.

146 uld be considered as part of a comprehensive nosocomial infection control program.

147 A synergistic combination of available nosocomial infection control strategies could prevent ne

148 s aureus (MRSA) is fundamental to modern-day nosocomial infection control, both for epidemiologic inv

149 ts with advanced cirrhosis and prevention of nosocomial infections could reduce this burden.

150 thors present a method for analyzing typical nosocomial infection data consisting of results from arb

151 The analysis of nosocomial infection data for communicable pathogens is

152 ssions during each phase, point estimates of nosocomial infections decreased by 22% during phase II a

153 on of inadequate antimicrobial treatment for nosocomial infections decreased during the course of the

154 en-day, 28-day, and hospital stay mortality; nosocomial infection, defined as an infection in blood o

155 have emerged as a cause of endocarditis and nosocomial infections despite being normal commensals of

156 However, surprisingly, nosocomial infection did not increase subsequent multipl

157 covering from inpatient vascular surgery and nosocomial infections did not occur.

158 nterobacter, genera commonly associated with nosocomial infections, dominate the preterm infant gut m

159 Nosocomial infections due to Pseudomonas aeruginosa have

160 logy, risk factors, and impact on outcome of nosocomial infections during extracorporeal membrane oxy

161 taxa containing species that commonly cause nosocomial infections (e.g., Enterobacteriaceae) that we

162 wth of three bacteria clinically relevant in nosocomial infections, evaluating their in vitro respons

163 atistically significant increase in rates of nosocomial infection for transfused patients regardless

164 rtunistic Gram-negative pathogen that causes nosocomial infections for which there are limited treatm

165 nd those developing symptoms later as having nosocomial infection has a positive predictive value and

166 ients out of the hospital, and thereby avoid nosocomial infections, has created an ever-growing need

167 -associated pneumonia, as well as with other nosocomial infections, has created an imperative to redu

168 essive multiple organ system dysfunction and nosocomial infections have a negative impact on survival

169 ity of illness, degree of organ dysfunction, nosocomial infection, hospital mortality, and other pote

170 alis is associated with a high proportion of nosocomial infections; however, little is known of the a

171 ssociated pneumonia (VAP) is the most common nosocomial infection in critically ill patients.

172 m difficile infection is a relatively common nosocomial infection in mechanically ventilated patients

173 ha production) and an increased risk of late nosocomial infection in some patients.

174 c factors contributing to the development of nosocomial infection in this high-risk population.

175 B. animalis subsp. lactis failed to prevent nosocomial infections in an acute-setting pediatric hosp

176 The incidence of nosocomial infections in children in developed countries

177 ns are needed for the empirical treatment of nosocomial infections in cirrhosis.

178 inosa is frequently a causative organism for nosocomial infections in critically ill patients and is

179 stridium difficile causes one of the leading nosocomial infections in developed countries, and therap

180 egative Combo 13 panel caused an outbreak of nosocomial infections in four patients (pneumonia, n = 2

181 of the incidence and microbiology of various nosocomial infections in patients with cancer-a large, i

182 nflower seed oil provides protection against nosocomial infections in preterm very low birthweight in

183 ciated bloodstream infections are similar to nosocomial infections in terms of frequency of various c

184 cterium animalis subsp. lactis in preventing nosocomial infections in the acute hospital setting.

185 coccus epidermidis are the leading causes of nosocomial infections in the United States and often are

186 enhance skin barrier function would prevent nosocomial infections in this population.

187 importation and transmission influence MRSA nosocomial infections in Veterans Affairs Medical Center

188 the association between RBC transfusion and nosocomial infection; in all these studies blood transfu

189 s is a major cause of community-acquired and nosocomial infections including the life-threatening con

190 tors underlying the outcome of P. aeruginosa nosocomial infections, including aspects related to the

191 stant opportunist causing difficult-to-treat nosocomial infections, including endocarditis, but there

192 Enterococcus faecalis is a leading agent of nosocomial infections, including urinary tract infection

193 Nosocomial infection is an important contributor to morb

194 r of neonatal patients at risk for acquiring nosocomial infections is increasing because of the impro

195 Enterococcus faecium is a leading source of nosocomial infections, it appears to lack many of the ov

196 rding Acinetobacter isolates responsible for nosocomial infections, little is known about these organ

197 Some nosocomial infections may be preventable in the pediatri

198 ference was found for the duration of common nosocomial infections [mean (range): 3.58 (1-7) vs. 3.79

199 dent predictors for development of ACLF were nosocomial infections, Model for Endstage Liver Disease

200 Nosocomial infections, mortality rates, and intensive ca

201 Effective strategies to prevent nosocomial infection must include continuous monitoring

202 tality, incidence of complications including nosocomial infection, neurologic decompensation (stroke)

203 that renders trauma patients susceptible to nosocomial infections (NI) and prolonged intensive care

204 ce and impact on adult patients' outcomes of nosocomial infections (NIs) occurring during venoarteria

205 tings worldwide empirical therapy in serious nosocomial infections now requires the use of carbapenem

206 osuppression and increased susceptibility to nosocomial infections observed in critically ill sepsis

207 lthcare settings, yet the greatest burden of nosocomial infection occurs in resource-restricted setti

208 r of abnormally functioning organ systems, a nosocomial infection occurs, or native cardiac function

209 0.05) and was associated independently with nosocomial infection (odds ratio (OR), 5.5, 95% confiden

210 ansfusions was independently associated with nosocomial infection (odds ratio 1.097; 95% confidence i

211 Nosocomial infection of health-care workers (HCWs) durin

212 sitive bacterium that can cause a variety of nosocomial infections of which urinary tract infections

213 Enterococcus faecium is a common cause of nosocomial infections, of which infective endocarditis i

214 [95% CI, 1.07-1.32], P = .001); presence of nosocomial infection (OR = 36.3 [95% CI, 9.71-135.96], P

215 also was associated with the development of nosocomial infections (OR, 3.2; 95% CI, 1.7-5.5; p < .01

216 Nosocomial infection, organ failure, and mortality in th

217 icroflora that has become a leading cause of nosocomial infections over the past several decades.

218 interval 1.96-53.32), and the development of nosocomial infections (p < 0.05, Mann-Whitney U test).

219 cells transfused, the greater the chance of nosocomial infection; p< 0.0001 chi-square).

220 ginosa is among the leading causes of severe nosocomial infections, particularly affecting critically

221 frequently complicated by the development of nosocomial infections, particularly Gram-negative pneumo

222 Pseudomonas aeruginosa is a major cause of nosocomial infections, particularly in immunocompromised

223 nt-line antibiotic used for the treatment of nosocomial infections, particularly those caused by meth

224 Nosocomial infections pose a significant threat to patie

225 sed percentages of blood MDSCs had increased nosocomial infections, prolonged intensive care unit sta

226 Leukoreduction tended to reduce the nosocomial infection rate but not significantly.

227 The nosocomial infection rate for the entire cohort was 5.94

228 The posttransfusion nosocomial infection rate was 14.3% in 428 evaluable pat

229 ss-of-fit test, which evaluated standardized nosocomial infection rates (observed vs. predicted nosoc

230 A subgroup analysis of nosocomial infection rates adjusted for probability of s

231 for hand hygiene of staff and reductions in nosocomial infection rates among patients.

232 erall mortality, multiple organ failure, and nosocomial infection rates for the entire cohort (n = 1,

233 Patient nosocomial infection rates for the major sites correlate

234 The nosocomial infection rates for the transfusion group (n

235 ervention phase, hand hygiene compliance and nosocomial infection rates improved suggesting that ongo

236 We determined the nosocomial infection rates in these groups while adjusti

237 female gender on multiple organ failure and nosocomial infection rates remains significant in both p

238 Nosocomial infection rates were compared among three gro

239 mial infection rates (observed vs. predicted nosocomial infection rates).

240 (defined daily doses per 1000 patient-days), nosocomial infection rates, and susceptibilities of all

241 rtality Prediction Model scores, have higher nosocomial infection rates, longer intensive care unit a

242 when evaluating interhospital comparison of nosocomial infection rates, quality assessment, interven

243 terial coatings on medical devices to reduce nosocomial infection rates.

244 important cause of community-associated and nosocomial infections related to exposure to aqueous env

245 rong predictor for subsequent acquisition of nosocomial infection (relative risk, 5.8; 95% confidence

246 CI, 0.68-1.90; I = 51.6%) and acquisition of nosocomial infections (relative risk, 1.13; 95% CI, 0.61

247 occurs and the relevance for acquisition of nosocomial infection remain undetermined.

248 23% lower risk of multiple organ failure and nosocomial infection, respectively.

249 h 2, 6, and 1.5 times the risk of developing nosocomial infection, respectively.

250 te measure of importation, transmission, and nosocomial infection, respectively.

251 Many nosocomial infections result from the ability of microor

252 colistin (COS) are emerging causes of severe nosocomial infections, reviving interest in the use of c

253 with severe traumatic brain injury to reduce nosocomial infection risk.

254 ntrinsic and extrinsic factors to adjust for nosocomial infections should be taken into consideration

255 Although the overall rate of nosocomial infections significantly decreased when combi

256 rging pathogen that causes a wide variety of nosocomial infections, spreads rapidly within hospitals,

257 Furthermore, nosocomial infections such as invasive aspergillosis and

258 ptococcus pneumoniae is a causative agent of nosocomial infections such as pneumonia, meningitis, and

259 onsible for a wide range of life-threatening nosocomial infections, such as septicemia, peritonitis,

260 iscrimination was compared with the National Nosocomial Infection Surveillance (NNIS) risk index.

261 sed on definitions set forth by the National Nosocomial Infection Surveillance System.

262 ) by participating hospitals in the National Nosocomial Infections Surveillance (NNIS) System in the

263 wide surveillance components of the National Nosocomial Infections Surveillance System hospitals duri

264 through routine surveillance, using National Nosocomial Infections Surveillance system methodology.

265 d by definitions and methods of the National Nosocomial Infections Surveillance System.

266 according to the guidelines of the National Nosocomial Infections Surveillance System.

267 for Disease Control and Prevention National Nosocomial Infections Surveillance.

268 reduced Centers for Disease Control National Nosocomial Infection Survey VAP (14/19; 73.6%) to (5/14;

269 in the literature, predicted by the National Nosocomial Infection System, or described by our own ins

270 sunflower oil are less likely to experience nosocomial infections than are control infants.

271 wer seed oil were 41% less likely to develop nosocomial infections than controls (adjusted incidence

272 to prevent this infection, as well as other nosocomial infections that complicate the hospital cours

273 ostridium difficile is the cause of emerging nosocomial infections that result in abundant morbidity

274 though classically thought to be primarily a nosocomial infection, the incidence of community-acquire

275 ity of survival by using MPM-0 scores showed nosocomial infection to occur at consistently higher rat

276 ntibiotic therapy were more likely to have a nosocomial infection, to have underlying cancer or diabe

277 The rate of nosocomial infection was a secondary outcome.

278 Patients whose nosocomial infection was diagnosed before transfusion we

279 Nosocomial infection was mainly associated with older ag

280 The prevalence of nosocomial infections was detected during 28 days of ICU

281 n into account that the overall incidence of nosocomial infections was lower than expected.

282 The number of patients with nosocomial infections was significantly reduced in the f

283 ridium difficile colitis, a leading cause of nosocomial infection, was studied in humans and in a mur

284 faecalis important for its ability to cause nosocomial infections, we suggest that the one-component

285 ood cells transfused, the odds of developing nosocomial infection were increased by a factor of 1.5.

286 rgan system dysfunction and development of a nosocomial infection were significantly associated with

287 Nosocomial infections were defined as infections that oc

288 of </= 20 TIPS/year, variceal bleeding, and nosocomial infections were independent risk factors for

289 ved, and predicted an increased incidence of nosocomial infection, whereas persistence of multiple or

290 Candida albicans is a common cause of nosocomial infections whose virulence depends on the rev

291 nisms, this review explores risk factors for nosocomial infection with methicillin-resistant Staphylo

292 BACKGROUND & AIMS: Nosocomial infections with Clostridium difficile present

293 Nosocomial infections with Klebsiella pneumoniae are a f

294 sessing the comorbidity-attributable risk of nosocomial infections with methicillin-resistant Staphyl

295 Enterococci are the leading cause of nosocomial infections worldwide and acquired resistance

296 Staphylococcus aureus is a major cause of nosocomial infections worldwide, and the rate of resista

297 mannii has emerged as a significant cause of nosocomial infections worldwide, there have been few inv

298 nii is a Gram-negative bacterium that causes nosocomial infections worldwide, with recent prevalence

299 obacter baumannii is a significant source of nosocomial infections worldwide.

300 , known to cause both community-acquired and nosocomial infections worldwide.